A new article published in JAMA reports that genetic variants may influence how patients respond to GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — including both how much weight they lose and what side effects they experience. The findings could help explain why results vary so widely from person to person.
What the Research Found
The JAMA Medical News article covers findings suggesting that individual genetic differences play a measurable role in determining a patient's response to GLP-1 receptor agonist medications. Specifically, the research indicates that genetic variants may affect two distinct outcomes: the degree of weight loss a patient achieves and the adverse effects they experience while on these drugs.
Semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro and Zepbound, were both cited in the discussion. These are currently among the most widely prescribed medications in this drug class.
Why This Matters for Patients
Anyone who has compared notes with a friend or family member on GLP-1 medications has likely noticed the results can differ dramatically. One person may lose significant weight with minimal side effects, while another on the same drug and dose struggles with nausea or sees modest results. Genetics may be a key piece of that puzzle.
If confirmed and expanded by further research, these findings could eventually support more personalized prescribing — helping clinicians anticipate who is likely to respond well and who may be at higher risk for side effects before starting treatment.
Key takeaway: Your DNA may partly determine how well Ozempic, Wegovy, Mounjaro, or Zepbound works for you and what side effects you experience — which could one day help doctors tailor prescriptions more precisely.
What This Does Not Mean Yet
It is important to note that this JAMA publication is a Medical News article discussing emerging findings, not a large-scale clinical trial with definitive conclusions. Routine genetic testing to guide GLP-1 prescribing is not currently a standard part of clinical practice. Patients should not interpret this research as a reason to stop or switch medications without speaking to their prescriber.
What to Watch For Next
This area of research — called pharmacogenomics — is growing rapidly alongside the explosion in GLP-1 prescriptions. As millions more patients use these medications, larger datasets will become available to identify which specific genetic variants matter most. Watch for follow-up studies that move from observational findings toward actionable genetic screening tools that could be used in clinical settings.
Frequently Asked Questions
As this field continues to evolve, it is important to make any decisions about your GLP-1 medication — including starting, stopping, or switching — in close consultation with your prescriber, who can evaluate your full medical history and individual circumstances.
- Peer-reviewed Medical News article, JAMA. Headline: 'Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.' Date not specified.